Positive agreement received for approval of AXANUM (low-dose...
AstraZeneca today announced that AXANUM, a fixed dose combination of 81 mg low-dose ASA (acetylsalicylic acid) and 20 mg esomeprazole, has received positive agreement for approval in 23 European Union...
View ArticleSanofi Pasteur to Evaluate Leukocare’s Stabilization Technology for Vaccines
Sanofi Pasteur and Leukocare biotechnology inked a cooperation agreement through which Sanofi’s vaccines division will evaluate Leukocare’s Stabilizing and Protecting Solutions (SPS) platform for...
View ArticleArk to Manufacture PsiOxus’ IV-Administered Oncolytic Virus for Clinical Trials
Ark Therapeutics negotiated a manufacturing partnership with PsiOxus Therapeutics for the latter’s ColoAd1 candidate for the treatment of colorectal cancer. Under terms of the agreement Ark will work...
View Article7TH DUESSELDORF SYMPOSIUM ON IMMUNOTOXICOLOGY Biology of the Arylhydrocarbon...
Heinrich Heine University Duesseldorf September 21 – 24, 2011 AhR research has taken great momentum recently, with a number of seminal discoveries, especially regarding its role in physiological...
View ArticleBody & Mind – HEALTH U.S. Doctor Cautious About HIV Vaccine
A New York City-based infectious disease specialist said a new vaccine developed by Spanish scientists, which could turn HIV into minor infection status, is reason to be cautiously optimistic. Dr....
View ArticleDow AgroSciences, Dualsystems Biotech Announce Profiling Agreement
INDIANAPOLIS & ZURICH, Mar 21, 2012 (BUSINESS WIRE) — Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company DOW -1.63% , and Dualsystems Biotech announced today, a drug...
View ArticleThermo announces its Maybridge line of bioactive molecules to accelerate drug...
Thermo Fisher Scientific Inc., one of the world leaders in serving science, has announced its 50th anniversary of Maybridge line of chemistry products – a continually evolving line of bioactive...
View ArticleInnovative screening tools accelerate drug discovery
Exclusively available in the UK from Cambio, Transcreener® HTS Assays and iuvo Microconduit array technology meet a demand for high performance tools which will speed discovery of new therapies....
View ArticleDrug Safety Executive Council™ to Participate in 8th North American Drug...
Dr. Ernie Bush, Vice President of Collaborative Projects for DSEC, speaks on industry trends in predictive toxicology The Drug Safety Executive Council™ (DSEC™) is pleased to announce that Dr. Ernie...
View ArticleAlder Scores $38M to Be Used for Its Two Clinical-Stage mAb Therapeutics
Alder BioPharmaceuticals has closed a $38 million Series D financing round. Proceeds of the financing will support clinical development of mAb therapeutic candidates ALD518 and ALD403. The money will...
View ArticleHumira Anchors Abbott’s 44% Increase in Net Income This Quarter Compared to...
Abbott Laboratories is reporting a 44% year-over-year leap in net income during the first quarter. The results were propelled by Humira, which has begun its expected march to overtaking Lipitor as the...
View ArticleIris Pharma, RxGen Partner on Integrated Ophthalmology Research Services
French firm Iris Pharma and RxGen have established an alliance through which they aim to provide fully integrated bench-to-bedside ophthalmology research services to the pharma and biotech industries...
View ArticleOligomerix Raises $2M for Tau Protease Inhibitor Alzheimer Disease Program
Oligomerix raised $2 million in a Series A round of financing to progress its tau protease inhibitor program for treating Alzheimer disease. The financing round comprises both the issue of new...
View ArticleNovo Nordisk, Kennedy Institute Partner on Rheumatoid Arthritis Drug and...
Novo Nordisk is partnering with Oxford University’s Kennedy Institute of Rheumatology in the U.K. for the discovery and development of new biomarkers and drug targets for rheumatoid arthritis and other...
View ArticleMiRagen Pockets $20M to Further miRNA-Based Drugs
MiRagen Therapeutics completed a $20 million Series B financing. The company will use the money to advance development of its miRNA-based therapeutics pipeline. The financing is being led by Remeditex...
View ArticleBiotie Regains Asia-Pacific Rights for VAP-1 Antibody Program from Seikagaku
Biotie Therapies and Seikagaku have agreed to terminate their license agreement for Biotie’s VAP-1 antibody program, BTT-1023. The decision also nixes Seikagaky’s option for Biotie’s VAP-1 SSAO small...
View ArticleAeres, IDRI to Take Preventive and Therapeutic TB Vaccine into Phase I
Nonprofit organizations Aeres and the Infectious Disease Research Institute (IDRI) are teaming up to develop the latter’s tuberculosis vaccine candidate, which is projected to start in clinical trials...
View ArticleEC Conditionally Approves Cell Therapeutics’ Pixantrone for Non-Hodgkin Lymphoma
The EC granted Cell Therapeutics’ Pixuvri® (pixantrone) conditional marketing authorization for use as monotherapy in the treatment of adult patients with multiply relapsed or refractory aggressive...
View ArticleBoehringer Ingelheim, Polyphor Partner on Macrocyclic Drug R&D
Boehringer Ingelheim and Polyphor inked a research collaboration and license agreement through which the latter will apply its MacroFinder® drug discovery platform to identify and optimize macrocyclic...
View ArticleBioCryst Halts Enrollment in Phase III Peramivir Trial
BioCryst said today it halted patient enrollment in a Phase III trial of its flu drug candidate peramivir. In a statement, the company cited an interim analysis by its data monitoring committee that...
View Article